National Board of Examinations

Question Paper Name :	DrNB CLINICAL HAEMATOLOGY Paper2
Subject Name :	DrNB CLINICAL HAEMATOLOGY Paper2
Creation Date :	2022-06-25 17:19:52
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB CLINICAL HAEMATOLOGY Paper2

1
3271871269
0
180
No
No
0
100
No
Cant View
No

DrNB CLINICAL HAEMATOLOGY Paper2

Section Id :	3271871272
Section Number :	1

Offline
Mandatory
10
100
Yes
105
0
1
3271871276
No

Question Number : 1 Question Id : 32718711742 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Eosinophils:

- a) Types and diagnostic criteria of hypereosinophilic syndromes. [5]
- b) Treatment approach to idiopathic hypereosinophilic syndrome. [5]

Question Number : 2 Question Id : 32718711743 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Macrophage Activation Syndrome:

- a) Describe pathophysiology of Macrophage Activation Syndrome in hematological disorders. [5]
- b) Describe various treatment strategies to treat Macrophage Activation Syndrome. [5]

Question Number : 3 Question Id : 32718711744 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

- Transfusion Associated Acute Lung Injury (TRALI):
- a) Describe the pathogenesis of TRALI. [4]
- b) How do you make a diagnosis of TRALI? [3]
- c) How do you manage TRALI? [3]

Question Number : 4 Question Id : 32718711745 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Platelets:

- a) Describe the structure and function of platelets in human body. [4]
- b) Describe various platelet function tests. [3]
- c) What are salient features of Wiscott Aldrich Syndrome. [3]

Question Number : 5 Question Id : 32718711746 Question Type : SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Immunoglobuins:

- a) Clinical manifestations and management of Primary IgA deficiency. [5]
- b) Clinical manifestation and management of X linked agammaglobulinemia. [5]

Question Number : 6 Question Id : 32718711747 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Plasma cells:

- a) Classification of plasma cell neoplasms and their diagnostic critera. [5]
- b) Management of Waldenstrom macroglobulinemia. [5]

Question Number : 7 Question Id : 32718711748 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time : 0

Nucleic acid testing for blood banks:

a) What is the importance of Nucleic acid testing for blood banks? [5]

b) What is the method for nucleic acid testing and for what pathogens is testing done in blood banks? [5]

Question Number : 8 Question Id : 32718711749 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Basophils:

- a) What is the structural and functional difference between mast cells and basophils? [5]
- b) Clinical and translational significance of basophils in hematological malignancies. [5]

Question Number : 9 Question Id : 32718711750 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Chronic Myelomonocytic Leukemia (CMML):

- a) Describe WHO classification of myeloprolifetaive neoplasms. [3]
- b) Risk stratification of CMML. [3]
- c) Describe treatment strategies for CMML. [4]

Question Number : 10 Question Id : 32718711751 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time : 0

Myeloproliferative Neoplasms (MPN):

- a) The molecular genetics of primary myelofibrosis. [5]
- b) Treatment options for primary myelofibrosis. [5]